BTSG

BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business.

However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold.

BrightSpring Health Services is leveraging AI and automation across hiring, intake, documentation, and patient care to improve productivity. The company reported 44% year-over-year adjusted EBITDA growth with margin expansion to 5.3%, with further benefits expected in late 2026 and early 2027. Peers Option Care Health and Addus HomeCare are similarly implementing AI-driven initiatives to enhance efficiency and reduce operational complexity.

BrightSpring Health Services (BTSG) receives a #2 (Buy) rating from Zacks with an A VGM Score and B Value Style Score. The company, a national home and community-based healthcare services provider, has seen three analysts revise earnings estimates upward in the last 60 days, with consensus estimates increasing to $1.82 per share and an average earnings surprise of +16.1%.